Athira Pharma Inc

NASDAQ:ATHA  
18.01
-0.07 (-0.39%)
Products, Regulatory

Athira Pharma Initiates Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Alzheimer’s Disease

Published: 12/01/2020 12:48 GMT
Athira Pharma Inc (ATHA) - Athira Pharma Announces Initiation of Patient Dosing for Act-ad Clinical Trial of Ath-1017, Small Molecule Hgf/met Activator, for Treatment of Mild-to-moderate Alzheimer’s Disease.
Athira Pharma Inc - Phase 2 Act-ad Clinical Trial Will Enroll Up to About 75 Patients With Mild-to-moderate Alzheimer's Disease in U.S. and Australia.